EUCTR2009-014368-20-Outside-EU/EEA进行中（未招募）不适用
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of AdolescentSubjects With Moderate to Severe Plaque-type Psoriasis - CADMUS
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adolescent subjects = 12 to < 18 years of age who have a diagnosis of plaque-type psoriasis with or without psoriatic arthritis (PsA) for at least 6 months; Are candidates for phototherapy or systemic treatment of psoriasis; Have screening laboratory test results within the study parameters.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 150
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Currently have nonplaque forms of psoriasis; Have used any therapeutic agent targeted at reducing interleukin-12 (IL-12) or interleukin-23 (IL- 23), including but not limited to ustekinumab and briakinumab; Received conventional systemic therapies or phototherapy within the last 4 weeks; Received biologic therapies within the last 3 months or 5 times the halflife of the agent (whichever is longer).
研究者
相似试验
招募中
1 期
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and RetreatmentModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code: 10071117Term: Plaque psoriasis Class: 10040785CTIS2023-505120-59-00Janssen - Cilag International600
进行中（未招募）
不适用
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial ofUstekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody,Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis andPreviously Treated with Biologic Anti-TNFa Agent(s)EUCTR2009-012265-60-FRCentocor B.V.300
进行中（未招募）
不适用
A Study of the Safety and Efficacy of Ustekinumab in Patients with Psoriatic Arthritis with and without Prior Exposure to Anti-TNF AgentsPsoriatic arthritisMedDRA version: 14.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2009-012265-60-DEJanssen Biologics B.V.300
进行中（未招募）
不适用
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial ofUstekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody,Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis Including Those Previously Treated with Biologic Anti-TNFa Agent(s) - PSUMMIT IIMedDRA version: 12.1Level: LLTClassification code 10037160Term: Psoriatic arthritisEUCTR2009-012265-60-SEJanssen Biologics B.V.300
进行中（未招募）
1 期
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis Including Those Previously Treated with Biologic Anti-TNFa Agent(s) - PSUMMIT IIMedDRA version: 12.1 Level: LLT Classification code 10037160 Term: Psoriatic arthritisPsoriatic ArthritisEUCTR2009-012265-60-GBJanssen Biologics B.V.